Data Insights

Aflibercept biosimilar by Sam Chun Dang Pharm for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Aflibercept biosimilar is under clinical development by Sam Chun Dang Pharm and currently in Phase III for Wet (Neovascular /...

Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration

Data Insights

Aflibercept biosimilar by Amgen for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Aflibercept biosimilar is under clinical development by Amgen and currently in Pre-Registration for Wet (Neovascular / Exudative) Macular Degeneration. According...

Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration

Data Insights

Aflibercept biosimilar by Amgen for Macular Edema: Likelihood of Approval

Aflibercept biosimilar is under clinical development by Amgen and currently in Pre-Registration for Macular Edema. According to GlobalData, Pre-Registration drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Macular Edema

Data Insights

Aflibercept biosimilar by Celltrion for Age Related Macular Degeneration: Likelihood of Approval

Aflibercept biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Age Related Macular Degeneration. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Age Related Macular Degeneration

Data Insights

Aflibercept biosimilar by Celltrion for Diabetic Macular Edema: Likelihood of Approval

Aflibercept biosimilar is under clinical development by Celltrion and currently in Phase III for Diabetic Macular Edema. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Diabetic Macular Edema

Data Insights

Aflibercept biosimilar by Qilu Pharmaceutical for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Aflibercept biosimilar is under clinical development by Qilu Pharmaceutical and currently in Phase III for Wet (Neovascular / Exudative) Macular...

Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration

Data Insights

Aflibercept biosimilar by Lupin for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Aflibercept biosimilar is under clinical development by Lupin and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration....

Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration

Data Insights

Aflibercept biosimilar by Alvotech for Choroidal Neovascularization: Likelihood of Approval

Aflibercept biosimilar is under clinical development by Alvotech and currently in Phase III for Choroidal Neovascularization. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Choroidal Neovascularization

Data Insights

Aflibercept biosimilar by Alvotech for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Aflibercept biosimilar is under clinical development by Alvotech and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration....

Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration